Lung

, Volume 192, Issue 1, pp 205–210 | Cite as

Antituberculosis Treatment and Hepatotoxicity in Patients with Chronic Viral Hepatitis

  • Yuag-Meng Liu
  • Yu-Jen Cheng
  • Yu-Lin Li
  • Chun-Eng Liu
  • Wu-Huei Hsu
Article
First Online:
Received:
Accepted:

Abstract

Background

Whether antituberculosis (anti-TB) treatment in patients with chronic viral hepatitis affects the incidence and onset time of drug-induced hepatotoxicity (DIH) is still controversial. The aim of this retrospective study was to find out whether chronic viral hepatitis affects the incidence and onset time of DIH.

Methods

All patients diagnosed with active TB and being treated at a tertiary referral hospital between 2002 and 2009 were identified from medical records, from which 553 patients were enrolled in the study. The incidence and onset of DIH in patients with and without chronic viral hepatitis (controls) were compared.

Results

The incidence of DIH was similar in patients with and without chronic hepatitis (8 % [32/392] vs. 7 % [11/161], P > 0.05). The incidence of transient liver function impairment (TLI) was significantly lower in controls than in chronic hepatitis patients (2 % [9/392] vs. 12 % [20/161], P < 0.001. The mean onset times of DIH in the control, hepatitis B virus (HBV), and hepatitis C virus (HCV) groups were not significantly different (40, 39, and 67 days, respectively, all P > 0.05). The mean onset times of TLI in the control, HBV, and HCV groups were significantly different (23, 48, and 68 days, respectively, all P < 0.05).

Conclusions

Liver function impairment during anti-TB therapy in patients with chronic viral hepatitis was due to mostly TLI, with TLI occurring later than in controls. Chronic viral hepatitis had no significant effect on the incidence of DIH.

Keywords

Antitubercular agents Hepatitis B virus Hepatitis C virus Drug-induced liver injury 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

The authors have no conflicts of interest to disclose.

References

  1. 1.
    Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282(7):677–686CrossRefPubMedGoogle Scholar
  2. 2.
    Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O’Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167(4):603–662. doi: 10.1164/rccm.167.4.603 CrossRefPubMedGoogle Scholar
  3. 3.
    Liao CM, Hsieh NH, Huang TL, Cheng YH, Lin YJ, Chio CP, Chen SC, Ling MP (2012) Assessing trends and predictors of tuberculosis in Taiwan. BMC Public Health 12:29. doi: 10.1186/1471-2458-12-29 PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Chen CJ, Yang HI (2011) Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 26(4):628–638. doi: 10.1111/j.1440-1746.2011.06695.x CrossRefPubMedGoogle Scholar
  5. 5.
    Lee MH, Yang HI, Jen CL, Lu SN, Yeh SH, Liu CJ, You SL, Sun CA, Wang LY, Chen WJ, Chen CJ (2011) Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991–1992. Gut 60(5):688–694. doi: 10.1136/gut.2010.220889 CrossRefPubMedGoogle Scholar
  6. 6.
    Døssing M, Wilcke JT, Askgaard DS, Nybo B (1996) Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 77(4):335–340CrossRefPubMedGoogle Scholar
  7. 7.
    Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK (1996) Risk factors for hepatotoxicity from antituberculosis drugs: a case–control study. Thorax 51(2):132–136PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Schaberg T, Rebhan K, Lode H (1996) Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9(10):2026–2030CrossRefPubMedGoogle Scholar
  9. 9.
    Amarapurkar DN, Prabhudesai PP, Kalro RH, Desai HG (1993) Antituberculosis drug-induced hepatitis and HBsAg carriers. Tuber Lung Dis 74(3):215–216CrossRefPubMedGoogle Scholar
  10. 10.
    Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TP, Lee SD (1997) A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 12(1):87–91CrossRefPubMedGoogle Scholar
  11. 11.
    Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, Kwon OJ (2005) Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 127(4):1304–1311. doi: 10.1378/chest.127.4.1304 CrossRefPubMedGoogle Scholar
  12. 12.
    Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM, Leung CC, Lai CL (2000) Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31(1):201–206. doi: 10.1002/hep.510310129 CrossRefPubMedGoogle Scholar
  13. 13.
    Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YS, Tsai YT, Lee PY, Ting LP, Lo KJ (1990) Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 98(2):502–504PubMedGoogle Scholar
  14. 14.
    Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE (1998) Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 157(6 Pt 1):1871–1876CrossRefPubMedGoogle Scholar
  15. 15.
    Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167(11):1472–1477. doi: 10.1164/rccm.200206-626OC CrossRefPubMedGoogle Scholar
  16. 16.
    Yew WW, Leung CC (2006) Antituberculosis drugs and hepatotoxicity. Respirology 11(6):699–707. doi: 10.1111/j.1440-1843.2006.00941.x CrossRefPubMedGoogle Scholar
  17. 17.
    Joint Tuberculosis Committee of the British Thoracic Society (1998) Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 53(7):536–548CrossRefGoogle Scholar
  18. 18.
    Turktas H, Unsal M, Tulek N, Oruc O (1994) Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Tuber Lung Dis 75(1):58–60. doi: 10.1016/0962-8479(94)90104-X CrossRefPubMedGoogle Scholar
  19. 19.
    Tost JR, Vidal R, Cayla J, Diaz-Cabanela D, Jimenez A, Broquetas JM (2005) Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis 9(5):534–540PubMedGoogle Scholar
  20. 20.
    Whittington RM (1991) Fatal hepatotoxicity of anti-tubercular chemotherapy. Lancet 338(8774):1083–1084CrossRefPubMedGoogle Scholar
  21. 21.
    Devarbhavi H, Dierkhising R, Kremers WK (2010) Antituberculosis therapy drug-induced liver injury and acute liver failure. Hepatology 52(2):798–799; author reply 799–800. doi: 10.1002/hep.23805 Google Scholar
  22. 22.
    Devarbhavi H, Singh R, Patil M, Sheth K, Adarsh CK, Balaraju G (2013) Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol 28(1):161–167. doi: 10.1111/j.1440-1746.2012.07279.x CrossRefPubMedGoogle Scholar
  23. 23.
    Kumar R, Bhatia V, Khanal S, Sreenivas V, Gupta SD, Panda SK, Acharya SK (2010) Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology 51(5):1665–1674. doi: 10.1002/hep.23534 CrossRefPubMedGoogle Scholar
  24. 24.
    Wang JY, Liu CH, Hu FC, Chang HC, Liu JL, Chen JM, Yu CJ, Lee LN, Kao JH, Yang PC (2011) Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect 62(6):448–455. doi: 10.1016/j.jinf.2011.04.005 CrossRefPubMedGoogle Scholar
  25. 25.
    Chien JY, Huang RM, Wang JY, Ruan SY, Chien YJ, Yu CJ, Yang PC (2010) Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int J Tuberc Lung Dis 14(5):616–621PubMedGoogle Scholar
  26. 26.
    Girling DJ (1982) Adverse effects of antituberculosis drugs. Drugs 23(1–2):56–74CrossRefPubMedGoogle Scholar
  27. 27.
    Sun HY, Chen YJ, Gau CS, Chang SC, Luh KT (2009) A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature. J Formos Med Assoc 108(2):102–111CrossRefPubMedGoogle Scholar
  28. 28.
    Liu Q, Garner P, Wang Y, Huang B, Smith H (2008) Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health 8:365. doi: 10.1186/1471-2458-8-365 PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Stickel F, Schuppan D (2007) Herbal medicine in the treatment of liver diseases. Dig Liver Dis 39(4):293–304. doi: 10.1016/j.dld.2006.11.004 CrossRefPubMedGoogle Scholar
  30. 30.
    Lee SD, Wang YJ, Lu RH, Chan CY, Lo KJ, Moeckli R (1994) Seroprevalence of antibody to hepatitis E virus among Chinese subjects in Taiwan. Hepatology 19(4):866–870CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Yuag-Meng Liu
    • 1
    • 2
  • Yu-Jen Cheng
    • 2
  • Yu-Lin Li
    • 2
  • Chun-Eng Liu
    • 2
  • Wu-Huei Hsu
    • 3
  1. 1.Graduate Institute of Clinical Medical ScienceChina Medical UniversityTaichungTaiwan, ROC
  2. 2.Department Infectious DiseaseChanghua Christian HospitalChanghuaTaiwan, ROC
  3. 3.Department of Internal MedicineChina Medical University HospitalTaichungTaiwan, ROC

Personalised recommendations